Nutritional Strategies in the Management of Alzheimer Disease: Systematic Review With Network Meta-Analysis

Journal of the American Medical Directors Association

Volumn 18, Issue 10, 2017, Pages 897.e13-897.e30

  Muñoz Fernández, Shirley Steffany ^a   Ivanauskas, Terry ^a   Lima Ribeiro, Sandra Maria ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Alzheimer disease; nutrition; systematic review

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; BIOLOGICAL MARKER; CARBOHYDRATE; CHOLINESTERASE INHIBITOR; GLYCEROL; INOSITOL; LIPID; MEDIUM CHAIN TRIACYLGLYCEROL; MEMANTINE; NUTRITION SUPPLEMENT; OCTANOIC ACID; OMEGA 3 FATTY ACID; PLACEBO; POLYPEPTIDE; PROLINE; TRACE ELEMENT; VITAMIN D; VITAMIN D DERIVATIVE;

AGING; ALZHEIMER DISEASE; ARTICLE; BIBLIOGRAPHIC DATABASE; CLINICAL TRIAL (TOPIC); COCHRANE LIBRARY; COGNITION; CONFIDENCE INTERVAL; DATA EXTRACTION; DIET SUPPLEMENTATION; EMBASE; FOOD; FUNCTIONAL STATUS; HUMAN; MEDLINE; META ANALYSIS; MINI MENTAL STATE EXAMINATION; NETWORK META-ANALYSIS; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NUTRIENT; OUTCOME ASSESSMENT; QUALITY CONTROL; RATING SCALE; RISK ASSESSMENT; SELECTION BIAS; STATISTICAL ANALYSIS; SYMPTOM; SYSTEMATIC REVIEW; THERAPY EFFECT; WEB OF SCIENCE; AGED; DIET THERAPY; FEMALE; MALE; MIDDLE AGED; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; NETWORK META-ANALYSIS;

EID: 85028321345     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2017.06.015     Document Type: Article

References (94)

1. World Health Organization. Neurological disorders. 2006, Public health challenges, Geneva Available at: http://www.who.int/mental_health/neurology/neurological_disorders_report_web.pdf. (Accessed 9 May 2015)
2. Dubois, B., Hampel, H., Feldman, H.H., et al. Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimer's Dement 12 (2016), 292–323.
3. Querfurth, H.W., LaFerla, F.M., Alzheimer's disease. N Engl J Med 362 (2010), 329–344.
4. Chen, Z., Zhong, C., Oxidative stress in Alzheimer's disease. Neurosci Bull 30 (2014), 271–281.
5. Karran, E., Mercken, M., De Strooper, B., The amyloid cascade hypothesis for Alzheimer's disease: An appraisal for the development of therapeutics. Nat Rev Drug Discov 10 (2011), 698–712.
6. Prince, M., Jackson, J., (eds.) World Alzheimer Report 2009. Alzheimer's Disease International, 2009 Available at: https://www.alz.co.uk/research/files/WorldAlzheimerReport.pdf. (Accessed 22 September 2014)
7. Joseph, J., Cole, G., Head, E., et al. Nutrition, Brain Aging, and Neurodegeneration. J Neurosci 29 (2009), 12795–12801.
8. Xu, W., Tan, L., Wang, H.-F., et al. Meta-analysis of modifiable risk factors for Alzheimer's disease. J Neurol Neurosurg Psychiatry 86 (2015), 1299–12306.
9. Steele, M., Stuchbury, G., Münch, G., The molecular basis of the prevention of Alzheimer's disease through healthy nutrition. Exp Gerontol 42 (2007), 28–36.
10. Swaminathan, A., Jicha, G.A., Nutrition and prevention of Alzheimer's dementia. Front Aging Neurosci, 6, 2014, 282.
11. Gillette Guyonnet, S., Abellan Van Kan, G., Andrieu, S., et al. IANA task force on nutrition and cognitive decline with aging. J Nutr Health Aging 11 (2007), 132–152.
12. Higgins, J.P.T., Green, S., (eds.) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [Updated March 2011], 2011, The Cochrane Collaboration, 1–639 Available at: handbook.cochrane.org. (Accessed 10 May 2014)
13. Liberati, A., Altman, D.G., Tetzlaff, J., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ, 339, 2009, b2700.
14. Review Manager (RevMan) [Computer program]. Version 5.3, 2014, The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen.
15. GRADEpro GDT. GRADEpro Guideline Development Tool [Software]. 2015. Available at: gradepro.org.
16. DerSimonian, R., Laird, N., Meta-analysis in clinical trials. Control Clin Trials 7 (1986), 177–188.
17. Van Valkenhoef, G., Tervonen, T., Zwinkels, T., et al. ADDIS: A decision support system for evidence-based medicine. Decis Support Syst 55 (2013), 459–475.
18. Brooks, S.P.B., Gelman, A.G., General methods for monitoring convergence of iterative simulations. J Comput Graph Stat 7 (1998), 434–455.
19. Higgins, J., Deeks, J., Altman, D., (eds.) Chapter 16: Special topics in statistics Higgins, J., Green, S., (eds.) Cochrane Handbook for Systematic Reviews of Interventions (Updated March 2011). Version 5, 2011, The Cochrane Collaboration, 488–534.
20. Folstein, M.F., Folstein, S.E., McHugh, P.R., “Mini-Mental State” A practical Method for Grading the Cognitive State of Patients for the Clinician. J Psychiatr Res 12 (1975), 189–198.
21. Galasko, D., Bennett, D., Sano, M., et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. Alzheimer Dis Assoc Disord 11 (1997), S33–S39.
22. Cummings, J., Mega, M., Gray, K., et al. The neuropsychiatric inventory: Comprehensive assessment of psychopathology in dementia. Neurology 44 (1994), 2308–2314.
23. Morris, J.C., The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology 43 (1993), 2412–2414.
24. Mayeux, R., Honig, L.S., Tang, M.-X., et al. Plasma Aβ 40 and Aβ 42 and Alzheimer's disease: Relation to age, mortality, and risk. Neurology 61 (2003), 1185–1190.
25. Blennow, K., Hampel, H., CSF markers for incipient Alzheimer's disease. Lancet Neurol 2 (2003), 605–613.
26. Hampel, H., Blennow, K., Shaw, L.M., et al. Total and Phosphorylated tau protein as biological markers of Alzheimer's disease. Exp Gerontol, 45, 2010, 30.
27. Swardfager, W., Lanctôt, K., Rothenburg, L., et al. A Meta-analysis of cytokines in Alzheimer's disease. Biol Psychiatry 68 (2010), 930–941.
28. Montine, T.J., Markesbery, W.R., Morrow, J.D., et al. Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease. Ann Neurol 44 (1998), 410–413.
29. Song, I.U., Chung, S.W., Kim, Y.D., et al. Relationship between the hs-CRP as non-specific biomarker and Alzheimer's disease according to aging process. Int J Med Sci 12 (2015), 613–617.
30. Komulainen, P., Lakka, T.A., Kivipelto, M., et al. Serum high sensitivity C-reactive protein and cognitive function in elderly women. Age Ageing 36 (2007), 443–448.
31. Ford, A.H., Flicker, L., Alfonso, H., et al. Vitamins B12, B6, and folic acid for cognition in older men. Neurology 75 (2010), 1540–1547.
32. Connelly, P.J., Prentice, N.P., Cousland, G., et al. A randomised double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer's disease. Int J Geriatr Psychiatry 23 (2008), 155–160.
33. Sun, Y., Lu, C.J., Chien, K.L., et al. Efficacy of multivitamin supplementation containing vitamins B6 and B12 and folic acid as adjunctive treatment with a cholinesterase inhibitor in Alzheimer's disease: A 26-week, randomized, double-blind, placebo-controlled study in Taiwanese patients. Clin Ther 29 (2007), 2204–2214.
34. Aisen, P.S., Schneider, L.S., Sano, M., et al. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease. JAMA 300 (2008), 1774–1783.
35. Stein, M.S., Scherer, S.C., Ladd, K.S., et al. A randomized controlled trial of high-dose vitamin D2 followed by intranasal insulin in Alzheimer's disease. J Alzheimer's Dis 26 (2011), 477–484.
36. Dysken, M.W., Sano, M., Asthana, S., et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: The TEAM-AD VA cooperative randomized trial. JAMA 311 (2014), 33–44.
37. Sano, M., Ernesto, C., Thomas, R.G., et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 336 (1997), 1216–1222.
38. Thomas, A., Iacono, D., Bonanni, L., et al. Donepezil, rivastigmine, and vitamin E in Alzheimer disease: A combined P300 event-related potentials/neuropsychologic evaluation over 6 months. Clin Neuropharmacol 24 (2001), 31–42.
39. Onofrj, M., Thomas, A., Luciano, A.L., et al. Donepezil versus vitamin E in Alzheimer's disease: Part 2: mild versus moderate-severe Alzheimer's disease. Clin Neuropharmacol 25 (2002), 207–215.
40. Lloret, A., Badía, M.-C., Mora, N.J., et al. Vitamin E paradox in Alzheimer's disease: It does not prevent loss of cognition and may even be detrimental. J Alzheimers Dis 17 (2009), 143–149.
41. Ringman, J.M., Frautschy, S.a., Teng, E., et al. Oral curcumin for Alzheimer's disease: Tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Alzheimers Res Ther, 4, 2012, 43.
42. Adair, J.C., Knoefel, J.E., Morgan, N., Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease. Neurology 57 (2001), 1515–1517.
43. Rubio-Perez, J.M., Morillas-Ruiz, J.M., Serum cytokine profile in Alzheimer's disease patients after ingestion of an antioxidant beverage. CNS Neurol Disord Drug Targets 12 (2013), 1233–1241.
44. Galasko, D.R., Peskind, E., Clark, C.M., et al. Antioxidants for Alzheimer disease: A randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol 69 (2012), 836–841.
45. Kessler, H., Pajonk, F.-G., Bach, D., et al. Effect of copper intake on CSF parameters in patients with mild Alzheimer's disease: A pilot phase 2 clinical trial. J Neural Transm 115 (2008), 1181–1187.
46. Kessler, H., Bayer, T.A., Bach, D., et al. Intake of copper has no effect on cognition in patients with mild Alzheimer's disease: A pilot phase 2 clinical trial. J Neural Transm 115 (2008), 1181–1187.
47. Barak, Y., Levine, J., Glasman a, et al. Inositol treatment of Alzheimer's disease: A double blind, cross-over placebo controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 20 (1996), 729–735.
48. Faxén-Irving, G., Freund-Levi, Y., Eriksdotter-Jönhagen, M., et al. Effects on transthyretin in plasma and cerebrospinal fluid by DHA-rich n - 3 fatty acid supplementation in patients with Alzheimer's disease: The OmegAD study. J Alzheimers Dis 36 (2013), 1–6.
49. Freund-Levi, Y., Hjorth, E., Lindberg, C., et al. Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: The OmegAD study. Dement Geriatr Cogn Disord 27 (2009), 481–490.
50. Freund-Levi, Y., Basun, H., Cederholm, T., et al. Omega-3 supplementation in mild to moderate Alzheimer's disease: Effects on neuropsychiatric symptoms. Int J Geriatr Psychiatry 23 (2008), 161–169.
51. Freund-Levi, Y., Eriksdotter-Jönhagen, M., Cederholm, T., et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: A randomized double-blind trial. Arch Neurol 63 (2006), 1402–1408.
52. Quinn, J.F., Raman, R., Thomas, R.G., et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease. JAMA 304 (2010), 1903–1911.
53. Shinto, L., Quinn, J., Montine, T., et al. A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer's disease. J Alzheimer Dis 38 (2014), 111–120.
54. Chiu, C.C., Su, K.P., Cheng, T.C., et al. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: A preliminary randomized double-blind placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 32 (2008), 1538–1544.
55. Kotani, S., Sakaguchi, E., Warashina, S., et al. Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction. Neurosci Res 56 (2006), 159–164.
56. Henderson, S.T., Vogel, J.L., Barr, L.J., et al. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: A randomized, double-blind, placebocontrolled, multicenter trial. Nutr Metab (Lond), 6, 2009, 31.
57. Scheltens, P., Kamphuis, P.J., Verhey, F.R., et al. Efficacy of a medical food in mild Alzheimer's disease: A randomized, controlled trial. Alzheimer's Dement 6 (2010), 1–10.e1.
58. Kamphuis, P.J., Verhey, F.R., Olde Rikkert, M.G., et al. Effect of a medical food on body mass index and activities of daily living in patients with Alzheimer's disease: Secondary analyses from a randomized, controlled trial. J Nutr Health Aging 15 (2011), 672–676.
59. Kamphuis, P.J., Verhey, F.R.J., Rikkert, O., et al. Efficacy of a medical food on cognition in Alzheimer's disease: Results from secondary analyses of a randomized, controlled trial. J Nutr Health Aging 15 (2011), 720–724.
60. Scheltens, P., Twisk, J.W.R., Blesa, R., et al. Efficacy of souvenaid in mild Alzheimer's disease: Results from a randomized, controlled trial. J Alzheimer's Dis 31 (2014), 225–236.
61. Planas, M., Conde, M., Audivert, S., et al. Micronutrient supplementation in mild Alzheimer disease patients. Clin Nutr 23 (2004), 265–272.
62. Shah, R.C., Kamphuis, P.J., Leurgans, S., et al. The S-Connect study: Results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer's disease. Alzheimers Res Ther, 5, 2013, 59.
63. De Waal, H., Stam, C.J., Lansbergen, M.M., et al. The effect of souvenaid on functional brain network organisation in patients with mild Alzheimer's disease: A randomised controlled study. PLoS One, 9, 2014, e86558.
64. Remington, R., Bechtel, C., Larsen, D., et al. A phase II randomized clinical trial of a nutritional formulation for cognition and mood in Alzheimer's disease. J Alzheimer's Dis 45 (2015), 395–405.
65. Leszek, J., Inglot, A.D., Janusz, M., et al. Colostrinin: A proline-rich polypeptide (PRP) complex isolated from ovine colostrum for treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Arch Immunol Ther Exp (Warsz) 47 (1999), 377–385.
66. Bilikiewicz, A., Gaus, W., Colostrinin (a naturally occurring, proline-rich, polypeptide mixture) in the treatment of Alzheimer's disease. J Alzheimers Dis 6 (2004), 17–26.
67. Zabłocka, A., Janusz, M., Macała, J., et al. Proline-rich polypeptide complex and its nonapeptide fragment inhibit nitric oxide production induced in mice. Regul Pept 125 (2005), 35–39.
68. Yenkoyan, K., Safaryan, K., Chavushyan, V., et al. Neuroprotective action of proline-rich polypeptide-1 in β-amyloid induced neurodegeneration in rats. Brain Res Bull 86 (2011), 262–271.
69. Castillo Lancellotti, C., Tur Marí, J.A., Uauy Dagach, R., Revisión sistemática del efecto de los folatos y otros nutrientes relacionados en la función cognitiva del adulto mayor. Nutr Hosp 27 (2012), 90–102.
70. Malouf, R., Grimley, E.J., Grimley Evans, J., Vitamin B6 for cognition. Cochrane Database Syst Rev, 2003, CD004393.
71. Rodríguez, J.-L., Qizilbash, N., López-Arrieta, J., Thiamine for Alzheimer's disease. Cochrane Database Syst Rev, 2001, CD001498.
72. Doets, E.L., Van Wijngaarden, J.P., Szczecinska, A., et al. Vitamin B12 intake and status and cognitive function in elderly people. Epidemiol Rev 35 (2013), 2–21.
73. Kennedy, D.O., B vitamins and the brain: Mechanisms, dose and efficacy—A review. Nutrients, 8, 2016, 68.
74. Isaac, M.G., Quinn, R., Tabet, N., Vitamin E for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev, 2008, CD002854.
75. Levine, J., Controlled trials of inositol in psychiatry. Eur Neuropsychopharmacol 7 (1997), 147–155.
76. Balion, C., Griffith, L.E., Strifler, L., et al. Vitamin D, cognition, and dementia; A systematic review and meta-analysis. Neurology 79 (2012), 1397–1405.
77. Hjorth, E., Zhu, M., Toro, V.C., et al. Omega-3 fatty acids enhance phagocytosis of alzheimer's disease-related amyloid-β42 by human microglia and decrease inflammatory markers. J Alzheimer's Dis 35 (2013), 697–713.
78. Hooijmans, C.R., Pasker-de Jong, P.C., de Vries, R.B., et al. The effects of long-term omega-3 fatty acid supplementation on cognition and Alzheimer's pathology in animal models of Alzheimer's disease: A systematic review and meta-analysis. J Alzheimers Dis 28 (2012), 191–209.
79. Wu, S., Ding, Y., Wu, F., et al. Omega-3 fatty acids intake and risks of dementia and Alzheimer's disease: A meta-analysis. Neurosci Biobehav Rev 48 (2015), 1–9.
80. Loef, M., Walach, H., The omega-6/omega-3 ratio and dementia or cognitive decline: A systematic review on human studies and biological evidence. J Nutr Gerontol Geriatr 32 (2013), 1–23.
81. Krikorian, R., Shidler, M.D., Dangelo, K., et al. Dietary ketosis enhances memory in mild cognitive impairment. Neurobiol Aging 33 (2012), 425.e19–425.e27.
82. Lim, W.S., Gammack, J.K., Van Niekerk, J., et al. Omega 3 fatty acid for the prevention of dementia. Cochrane Database Syst Rev, 2006, CD005379.
83. Issa, A.M., Mojica, W.A., Morton, S.C., et al. The efficacy of omega-3 fatty acids on cognitive function in aging and dementia: A systematic review. Dement Geriatr Cogn Disord 21 (2006), 88–96.
84. Mazereeuw, G., Lanctôt, K.L., Chau, S.A., et al. Effects of omega-3 fatty acids on cognitive performance: A meta-analysis. Neurobiol Aging 33 (2012), 1482.e17–1482.e29.
85. Rijpma, A., Meulenbroek, O., Olde Rikkert, M.G., Cholinesterase inhibitors and add-on nutritional supplements in Alzheimer's disease. Ageing Res Rev 16 (2014), 105–112.
86. Onakpoya, I.J., Heneghan, C.J., The efficacy of supplementation with the novel medical food, Souvenaid, in patients with Alzheimer's disease: A systematic review and meta-analysis of randomized clinical trials. Nutr Neurosci 20 (2015), 1–9.
87. Jacobs, D.R., Gross, M.D., Tapsell, L.C., Food synergy: An operational concept for understanding nutrition. Am J Clin Nutr 89 (2009), 1543S–1548S.
88. Jacobs, D.R., Tapsell, L.C., Food, not nutrients, is the fundamental unit in nutrition. Nutr Rev 65 (2007), 439–450.
89. Messina, M., Lampe, J.W., Birt, D.F., et al. Reductionism and the narrowing nutrition perspective. J Am Diet Assoc 101 (2001), 1416–1419.
90. Jacobs, D.R., Steffen, L.M., Nutrients, foods, and dietary patterns as exposures in research: A framework for food synergy. Am J Clin Nutr 78 (2003), 508–513.
91. Singh, B., Parsaik, A.K., Mielke, M.M., et al. Association of Mediterranean diet with mild cognitive impairment and Alzheimer's disease: A systematic review and meta-analysis. J Alzheimer's Dis 39 (2014), 271–282.
92. Lourida, I., Soni, M., Thompson-Coon, J., et al. Mediterranean diet, cognitive function, and dementia. Epidemiology 24 (2013), 479–489.
93. Wengreen, H., Munger, R., Prospective study of dietary approaches to stop hypertension–and Mediterranean-style dietary patterns and age-related cognitive change: The Cache County Study. Am J Clin Nutr 98 (2013), 1263–1271.
94. Morris, M.C., Tangney, C.C., Wang, Y., et al. MIND diet associated with reduced incidence of Alzheimer's disease. Alzheimer's Dement 11 (2015), 1007–1014.